NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00171470
- Locations
- 🇺🇸
http://www.novartisclinicaltrials.com/etrials/DiseaseID21/Dyspepsia-clinical-trials.go, East Hanover, New Jersey, United States
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 252
- Registration Number
- NCT00171171
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
🇱🇧Ali Taher, Beirut, Lebanon
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171938
Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 47
- Registration Number
- NCT00171743
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1461
- Registration Number
- NCT00171990
- Locations
- 🇦🇺
Novartis Investigative Site, North Ryde, Australia
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00171769
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 234
- Registration Number
- NCT00170781
- Locations
- 🇨🇭
For Site Information, contact Novartis Pharma AG, Basel, CH, Switzerland
🇩🇪Novartis, Nuernberg, Germany
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-10-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 419
- Registration Number
- NCT00170898
- Locations
- 🇬🇧
For site information contact, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00171626
- Locations
- 🇺🇸
Novartis Consumer Health Inc, Parsippany, New Jersey, United States
Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 450
- Registration Number
- NCT00171691
- Locations
- 🇺🇸
Novartis Consumer Health Inc., Parsippany, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath